Faculty Collaboration Database

First report that prior ECMO therapy does not preclude hematopoietic cell transplantation. Pediatr Hematol Oncol 2018 May;35(4):245-249

Date

12/21/2018

Pubmed ID

30570427

DOI

10.1080/08880018.2018.1505989

Scopus ID

2-s2.0-85059008833 (requires institutional sign-in at Scopus site)

Abstract

Hematopoietic stem cell transplantation (HCT) offers a potential cure for patients with high-risk malignancies but carries a risk of death from transplant-related complications. Extracorporeal membrane oxygenation (ECMO) is often considered a contraindication to transplant with the assumption that lung injury puts the patient at risk for pulmonary complications post-HCT. Although patients who have required prolonged intubation show gradual improvement in pulmonary function over time, there is little data on pulmonary functional recovery after ECMO which makes assessment pre-HCT difficult. We present a case series of two patients with high-risk hematologic malignancies, who had previously received ECMO and then underwent reduced-intensity HCT. Although both patients had complications post-HCT, neither patient suffered significant pulmonary toxicity related to their prior ECMO exposure. We conclude that, although patients who have previously been treated with ECMO remain at high risk for complications after transplant, but they should not be excluded from consideration for reduced intensity transplantation.

Author List

Broglie L, Phelan R, Talano JA

Authors

Larisa Broglie MD, MS Assistant Professor in the Pediatrics department at Medical College of Wisconsin
Rachel A. Phelan MD, MPH Associate Professor in the Pediatrics department at Medical College of Wisconsin
Julie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Child, Preschool
Extracorporeal Membrane Oxygenation
Hematopoietic Stem Cell Transplantation
Humans
Infant
Treatment Outcome